CN101978934B - Multi-layer coaxial vaso-occlusive device - Google Patents
Multi-layer coaxial vaso-occlusive device Download PDFInfo
- Publication number
- CN101978934B CN101978934B CN2010102779962A CN201010277996A CN101978934B CN 101978934 B CN101978934 B CN 101978934B CN 2010102779962 A CN2010102779962 A CN 2010102779962A CN 201010277996 A CN201010277996 A CN 201010277996A CN 101978934 B CN101978934 B CN 101978934B
- Authority
- CN
- China
- Prior art keywords
- vascular occlusion
- implant according
- occlusion implant
- open area
- hydrogel
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Images
Abstract
A vaso-occlusive device includes inner, intermediate, and outer elements arranged coaxially. The inner element is a filamentous element, preferably a microcoil. The intermediate element is made of a non-metallic material, preferably an expansile polymer. The outer element is substantially non-expansile and defines at least one gap or opening through which the intermediate element is exposed. In a preferred embodiment, when the intermediate element is expanded, it proturdes through the at least one gap or opening in the outer element and assumes a configuration with an undulating, convexly-curved outer surface defining a chain of arcuate segments, each having a diameter significantly greater than the diameter of the outer element. The expanded configuration of the intermediate element minimizes friction when the device is depolyed through a microcatherter, thereby reducing the likelihood of buckling while maintaining excellent flexibility. The result is a device with enhanced pushability and trackability when deployed through a microcatheter.
Description
Cross reference to related application
The application is that sequence number is the part continuation application of the application of 10/631,981 common pending trial; Said application was submitted on July 31st, 2003; The said sequence number that requires to submit on July 31st, 2002 in first to file is 60/400; The right that 013 provisional application produces down at 35U.S.C.Section119 (e), the disclosure content of said provisional application is cited at this as a reference.
The research of federal funding or exploitation
Inapplicable.
Technical field
The present invention relates to be used for aneurysm and similar vascular lesion are carried out vascular occlusion (vaso-occlusive) device of thromboembolism, like vascular occlusion turn and similar installation.Particularly, the present invention relates to that existing two-layer or two elements coaxial vaso-occlusive device is particularly had the improvement that polymer coating or tectal those devices have been done.Particularly, the present invention relates to a kind of three layers or element coaxial vaso-occlusive device that improved durability, pushing away property and trackability are provided in microtubular inside.The characteristic that is known as " trackability " refer within another intervention device or on advance the conveniency of an intervention device, and this characteristic relates to friction and flexible.
Background technology
Vascular occluding device is normally used in the vascular system of human body so that stop blood flow to pass through vascular (vessel) by means of forming embolus.Vascular occluding device also is used in coming from the aneurysm of vascular, forming embolus.Vascular occluding device can be formed by one or more elements, and said one or more elements are transferred in the vascular system through conduit or similar mechanism usually.
Under some clinical settings, blood vessel embolism need be provided.For example, vascular embolization be used to control vascular bleed, make the blood supply of tumor inaccessible and to aneurysm particularly intracranial aneurysm carry out obturation.In recent years, be used to treat aneurysmal vascular embolization and caused a lot of concerns.Adopted multiple different treatment modalities in the prior art.A kind of method that has a bright future is to utilize thrombosed microcoils.These microcoils can be processed by metal alloy with biocompatibility (normally platinum and tungsten) or suitable polymer.If be made of metal, then turn can be provided with Dacron (terylene) fiber so that increase thrombogenicity.Turn is configured to the tremulous pulse position through microtubular.Disclose in the instance of the microcoils United States Patent (USP) below: license to 4,994,069 of Ritchart etc.; License to 5,133,731 of Butler etc.; License to 5,226,911 of Chee etc.; License to 5,312,415 of Palermo; License to 5,382,259 of Phelps etc.; License to Dormandy, 5,382,260 of Jr. etc.; License to Dormandy, 5,476,472 of Jr. etc.; License to 5,578,074 of Mirigian; License to 5,582,619 of Ken; License to 5,624,461 of Mariant; License to 5,645,558 of Horton; License to 5,658,308 of Snyder; With license to 5,718,711 of Berenstein etc.
The microcoils of the particular type of having achieved success to a certain extent is at the Guglielmi Detachable Coil (the removable turn that takes off of Guglielmi) (" GDC ") described in the United States Patent(USP) No. 5,122,136 that licenses to Guglielmi etc.GDC adopts through the soldering connection and is fixed to the platinum filament turn on the rustless steel transmission line.After turn is placed in aneurysm inside, thereby electric current is applied on this transmission line with electrolysis mode and makes the soldered joint place produce division, turn and transmission line is torn open thrown off.The electric current that applies also makes and on turn, has formed positive charge so that attract electronegative hemocyte, platelet and celloglobulin former, increased the thrombogenicity of turn thus.Multiple turn with different-diameter and length can be squeezed in the aneurysm and is full of fully until aneurysm.Therefore turn has formed thrombosis and has kept said thrombosis in aneurysm, thereby has suppressed the displacement of said thrombosis and cracked.
The advantage of GDC process is, if having the ability of regaining coil and coil being reorientated when its desired location is left in the turn migration, and has promotion and in aneurysm, forms the enhanced ability of stablizing thrombosis.
Licensing to Greene, the United States Patent (USP) 6,299 of Jr. etc.; 619 neutralizations license to Greene, the United States Patent (USP) 6,602 of Jr. etc.; Example shows the progress that obtains recently in the microcoils field of microcoil vaso-occlusive in 261, and said two patents have all been transferred assignee of the present invention.These Patent publish comprise the vascular occluding device of microcoils, said microcoils has the one or more inflatable elements on the outer surface that is arranged on turn.Said inflatable element can be formed by any expandable polymer hydrogel in the multiple expandable polymer hydrogel; Or another kind of optional mode is, by when being exposed to physiological environment such as blood flow, producing expansible environmental sensitivity polymer formation in response to the variation of ambient parameter (like temperature or pH).
Although the microcoils with inflatable element for example to the aneurysm with multiple size and configuration carry out thromboembolism aspect shown bright future, inflatable element has increased the frictional force between vascular occluding device and the configuration microtubular that this device utilized.In addition, according to the configuration and the material of inflatable element, the flexibility of device possibly decrease.These factors possibly cause producing a kind of device that does not still possess pushing away property of the best (to producing the resistance of flexing) and have the trackability (as stated) of reduction.
Therefore, existingly hope for a long time but still unsatisfied needs provide and a kind ofly have all advantages of inflatable element types of devices and demonstrate enhanced pushing away property in addition and the microcoils vascular occluding device of trackability and good wear properties.
Summary of the invention
In the broadest sense, the present invention relates to a kind of vascular occluding device, said vascular occluding device comprises three coaxial element: element in the elongated flexible, filamentous; The nonmetal intermediary element that coaxially centers on said interior element and closely contact with said interior element; The external component that coaxially centers on said intermediary element and closely contact with said intermediary element, said external component comprises one or more openings or gap, said intermediary element comes out through said opening or gap.
In a preferred embodiment of the invention; Element exists with the form by the radiopaque metal helical coil with biocompatibility in said; And said intermediary element is conformal coating or the layer that is positioned on the said element; Said conformal coating or layer are processed by soft polymeric material, and said soft polymeric material is expandable polymer preferably.Advantageously, polyalcohol hydrogel is when being exposed to the physiological environment of blood flow for example, to produce expansible environment-responsive hydrogel.Polymer advantageously biology can absorb or Biodegradable polymeric.
Said external component is advantageously except closely reeling (" close-wound (close around) at near-end and distal end sections place ") reeled by loosely (" open-wound (pine around) ") spiral type " hairspring (over-coil) " on said intermediary element.Said close around near-end and distal end sections support said in element; Prevent said in element sustain damage reorientating in the process of layoutprocedure and any necessity, simultaneously also the said near-end of said device and far-end with said intermediary element securely harness in said on the element and suppressed to state said hydrogel generation expansion of intermediary element at the said respective end place of said device.Said pine between said proximal segment and said distal end sections has formed single successive spiral shaped openings around portion's section, and said intermediary element expands through said opening.The helical configuration of said opening makes that thereby said expansible polymeric intermediate element is stressed to demonstrate between the turn of said hairspring the radially configuration of the chain of outwardly directed arcuate segments, rather than demonstrates the configuration of the continuous polymer layer with successive continual outer surface.Since each section in the said arcuate segments mainly at tangent line contact point place or the position of contiguous said tangent line contact point contact (for example in layoutprocedure) with the inner surface of microtubular; Therefore compare with the continuous axial polymer element, total contact area of said intermediary element is reduced.The contact area of this minimizing has correspondingly reduced the total friction between said polymeric layer and the said microtubular, has reduced the resistance of controlling said device thus.Said pine has also formed hinge point between the said arcuate segments in said polymeric intermediate element around portion's section, has improved the overall flexibility of said device thus.
Passed through experiment confirm; Because said external component and because the reduction friction that said external component and interaction between the said intermediary element bring and improve flexible advantage make with for example of the prior art have to be positioned on the outer surface or along the expandable polymer coating of outer surface setting or the microcoils device of element compare, the pushing away property and the trackability of device constructed in accordance have obtained enhancing.
The present invention provides a kind of microcoils vascular occluding device with inflatable element thus; Said inflatable element allows said device very effectively multiple vascular lesion to be carried out thromboembolism like the aneurysm with multiple shape, size and position, and compared with prior art also demonstrates enhanced pushing away property and trackability.
Description of drawings
Fig. 1 is the perspective view of vascular occluding device according to a preferred embodiment of the present invention;
Fig. 2 is the axial cutaway view of device shown in Figure 1;
Fig. 3 is the perspective view similar with device shown in Figure 1, and the expandable polymer intermediary element that is in swelling state has been shown among the figure;
Fig. 4 is the axial cutaway view of device shown in Figure 3;
Fig. 5 is the cutaway view along line 5-5 intercepting shown in Figure 2, but among the figure first variations of the present invention has been shown, and wherein said interior element comprises two coaxial spiral type microcoils;
Fig. 6 is the cutaway view similar with device shown in Figure 5, but among the figure second variations of the present invention has been shown, and wherein said interior element comprises three coaxial spiral type microcoils;
Fig. 7 is the cutaway view similar with device shown in Figure 5, but among the figure the 3rd variations of the present invention has been shown, and wherein said interior element comprises the spiral type microcoils that limits the lumen that comprises solid coaxial core body;
Fig. 8 is the cutaway view similar with device shown in Figure 5, but among the figure the 4th variations of the present invention has been shown, and wherein said interior element comprises the spiral type microcoils that limits the lumen that comprises the coaxial core body of hollow tubular; With
Fig. 9 is the perspective view of another optional embodiment of the present invention.
The specific embodiment
Referring to Fig. 1-Fig. 4, vascular occluding device 10 according to a preferred embodiment of the present invention comprises three elongated coaxial element: interior element 11, nonmetal intermediary element 12 and cover the nondistensible external component 13 of at least a portion of said intermediary element.Intermediary element 12 all closely contacts with external component 13 with interior element 11.
Interior element 11 is formed by the elongated filament or the tinsel of flexibility, and the elongated filament of said flexibility or tinsel are preferably processed by visible material under various medical imaging means such as X-ray, NMR-imaging (MRI) or ultrasound wave.Interior element 11 is preferably formed by the tinsels of certain-length, and the tinsel of said certain-length has radiopaque metal of biocompatibility such as any metal in platinum, tantalum, tungsten, gold, titanium, nitinol, rustless steel, ELgiloy (cobalt-chromium-nickel) or other alloy well known in the art is processed by multiple.Another kind of optional mode is, interior element can be by nonmetallic materials such as polymer, collagen, protein, medicine, biomaterial (for example cell material and gene), biologically active agents, treatment is processed with the combination of chemical compound or these materials or comprise above-mentioned material.If interior element is processed by radioparent material, then should be advantageously internally element mix or dipping or chemical modification are visible so that make it under one or more imaging technique effects.Another kind of optional mode is that interior element can be processed by the material that under MRI or ultrasound wave means, has high observability.Interior element 11 can be configured as multiple configuration, and this includes, but not limited to turn, bar, pipeline, cable, fabric, cut-out pipe or other elongated flexible form.As shown in the figure, interior element exists with the form of helical coil, and said form possibly be preferred form.In a particular embodiment, interior element is shaped as the multifibres coil configuration at least in part, is that the disclosure content of said patent application is cited at this as a reference described in 2004/0006362 the total U.S. Patent application as publication number.
Most preferred material is the environment-responsive hydrogel, and for example publication number is the sort of hydrogel described in 2002/0176880 the U.S. Patent application, and the disclosure content of said patent application is cited at this as a reference.Especially, publication number is that the hydrogel described in 2002/0176880 the U.S. Patent application has in response to this ambient parameter such as pH or variation of temperature and produces the expansible type of controlled volume.These hydrogels are to comprise (a) at least a monomer and/or polymer through formation, and at least a portion of said at least a monomer and/or polymer is responsive for the variation of ambient parameter; (b) cross-linking agent; (c) liquid mixture of polymerization initiator prepares.If desired, then pore former (porosigen) (for example NaCl, ice crystal or sucrose) can be added in the mixture, thereby and from the gained solid hydrogel, is removed subsequently to provide and has abundant permeability so that the hydrogel that allows cell to grow into.The alkylene unsaturated monomer that has ionizable functional group (for example amine, carboxylic acid) through introducing provides controlled expansion rate.For example, if acrylic acid is introduced in the cross-linked network, make carboxylic acid protonated thereby then in low pH value solution, hydrogel cultivated.After rinsing out too much low pH value solution and hydrogel carried out drying, hydrogel can be conducted through to be filled with and be in the salt under physiology's pH value or be filled with in the microtubular of blood.Have only hydroxy-acid group is carried out after the deprotonation, hydrogel could produce expansion.On the contrary, be introduced in the cross-linked network, amine carried out deprotonation thereby then in high pH value solution, hydrogel cultivated if contain the monomer of amine.After rinsing out too much high pH value solution and hydrogel carried out drying, hydrogel can be conducted through and be filled with the microtubular that is in the salt under physiology's pH value or is filled with blood.Have only to amine groups carry out protonated after, hydrogel could produce expansion.
More particularly, in the preferred dosage form of hydrogel, monomer solution comprises alkylene unsaturated monomer, the unsaturated cross-linking agent of alkylene, pore former and solvent.Selected monomeric at least a portion, preferred 10%-50%, and more preferably 10%-30% must have pH sensitivity.Preferred pH sensitive monomer is an acrylic acid.The derivant of methacrylic acid and two kinds of acid also will provide pH sensitivity.Owing to utilize the engineering properties of the sour prepared hydrogels except these are sour relatively poor, therefore should select to provide the monomer of additional mechanical character.Being used to the preferred monomers of engineering properties is provided is acrylamide, thus said monomer can with above-mentioned pH sensitive monomer in one or more be used in combination additional compressive strength or other engineering properties be provided.The preferred concentration of monomer in solvent is in the scope of 20%w/w to 30%w/w.
Cross-linking agent can be any multi-functional alkylene unsaturated compound, N preferably, N '-methylene-bisacrylamide.Hydrogel material has biological degradability if desired, then should select biodegradable cross-linking agent.The concentration of cross-linking agent in solution should be less than about 1%w/w, and preferably less than about 0.1%w/w.
Through being suspended in, pore former reaches the porosity that the supersaturation suspended state provides hydrogel material in the monomer solution.Also capable of usingly be insoluble in the monomer solution but dissolve in the pore former in the cleaning solution.Sodium chloride is preferred pore former, but potassium chloride also capable of using, ice, sucrose and sodium bicarbonate.Preferably the particle size with pore former is controlled to be less than about 25 microns, is more preferably less than about 10 microns.Low particle size helps the suspension of pore former in solvent.The preferred concentration of pore former in monomer solution is in from about 5%w/w to the scope of about 50%w/w, more preferably in from about 10%w/w to the scope of about 20%w/w.Another kind of optional mode is can save pore former and can make non-porous hydrogel.
Solvent if desired is then based on the dissolubility selective solvent of monomer, cross-linking agent and pore former.If use liquid monomer (for example, the 2-hydroxyethyl methacrylate), then needn't use solvent.Preferred solvent is a water, but ethanol also capable of using.The preferred concentration of solvent is in from about 20%w/w to the scope of about 80%w/w, more preferably in from about 50%w/w to the scope of about 80%w/w.
Crosslink density has appreciable impact to the engineering properties of these hydrogel materials.Can control best crosslink density (and therefore to engineering properties) through the variation of monomer concentration, crosslinker concentration and solvent strength.Can realize monomeric crosslinked through redox, radiation and heat.Can under the situation of utilizing suitable initiator through ultraviolet light and visible light or under the situation of not utilizing initiator the crosslinking with radiation through ionizing radiation (for example electron beam or gamma ray) realization monomer solution.The cross-linked evocating agent of preferred type is the cross-linked evocating agent through the redox effect.The particular instance that can be used for this reducing/oxidizing (red/ox) initiator among this embodiment of the present invention is Ammonium persulfate. and N, N, N ', N '-tetramethylethylenediamine.
After accomplishing polymerization, water, ethanol or other one or more suitable cleaning solutions clean hydrogel so that remove one or more pore formers, any not one or more monomers and any oligomer that is not introduced into of the remnants of effect.This process preferably realizes through originally in distilled water, hydrogel being cleaned.
As stated, through carrying out protonated/deprotonation and realize control to the expansion rate of hydrogel to being present in ionizable functional group on the hydrogel network.In case prepared hydrogel and too much monomer and pore former by flush away, then can implement to control the step of expansion rate.
Be introduced among the embodiment in the hydrogel network in pH sensitive monomer, in low pH value solution, hydrogel cultivated with hydroxy-acid group.Free proton in the solution carries out protonated to the hydroxy-acid group on the hydrogel network.The pH value of the persistent period of incubation and temperature and solution has influenced the controlled quentity controlled variable to expansion rate.Generally, the persistent period of incubation and temperature and in direct ratio to expansible controlled quentity controlled variable, the solution pH value is then with inversely proportional to expansible controlled quentity controlled variable.The water content that it has been determined that Treatment Solution has also influenced the control of expanding.With regard to this respect, hydrogel can produce more to expand and think in Treatment Solution has increased the quantity that can be used for carrying out protonated hydroxy-acid group.Need be optimized so that control expansion rate to the full extent water content and pH.After accomplishing cultivation, too much Treatment Solution is carried out drying by flush away and to hydrogel material.Observe, compare, be decreased to littler size through hydrogel size after drying of hanging down the pH value solution-treated with untreated hydrogel.Because need through these hydrogel materials of microtubular transmission, therefore above-mentioned effect is the effect that needs.
Be introduced in the hydrogel network if having the pH sensitive monomer of amine groups, then in high pH value solution, hydrogel cultivated.Deprotonation is occurring on the amine groups of hydrogel network under the high pH value.The pH value of the persistent period of incubation and temperature and solution has influenced the controlled quentity controlled variable to expansion rate.Usually, the persistent period of incubation, temperature and solution pH value are with in direct ratio to expansible controlled quentity controlled variable.After accomplishing cultivation, too much Treatment Solution is carried out drying by flush away and to hydrogel material.
For the embodiment of vascular occluding device with the intermediary element that forms by the expandable polymer hydrogel; When middle element 12 produces expansion; Not by the zone passage opening or the gap of the softish conformal intermediary element 12 of external component 13 coverings or restriction; Or between the turn of external component 13, extend radially outward (being described below), thereby make the corrugated outer surface that forms the chain that comprises arcuate segments under the effect of the restriction that applies at external component 13.Because the arcuate segments of corrugated outer surface only contacts with the inner wall surface of the configuration microtubular that this device utilized at the tangent line contact point place on contiguous each section summit or the position of approaching said tangent line contact point; Therefore make; Compare with the continuous or slick surface of same material, this wavy or arcuate configuration provides the friction that alleviates.
Opening in the external component 13 preferably makes; Along the quite long part of device length, the open area of external component 13 preferably between total outer surface region of the near-end boundary of this part of device length and the device between the far-end boundary at least about 20% and more preferably greater than about 40%.For example; In position near the device end; External component 13 can have the open area (promptly less than about 20%) of relatively low percentage ratio; And for the more most device length between the end sections of device, external component 13 can have the open area of bigger percentage ratio (promptly at least about 20% and be preferably greater than about 40%), thereby allows intermediary element 12 to come out to a greater degree through external component 13.The part at least about 75% external component 13 of cladding system total length preferably will have the open area of bigger percentage ratio.
In most preferred embodiment; Device comprises the intermediary element 12 of interior element 11 that the helical coil by the tight coiling of biocompatibility metal silk (for example platinum alloy) (" close around ") forms, hydrophilic expandable polymer (for example hydrogel) and the external component 13 that exists with the form of the helical coil of biocompatibility metal or polymer, said turn be pine in most of length range around and have close around proximal segment 14 with close around distal end sections 15.The pine of external component 13 limits single successive spiral shaped openings or gap around part.Turn is preferably processed by the tinsel with the diameter that is no more than about 0.15mm.The pitch of the turn that external component 13 is included can reach ten times of the filament diameter that is wound into turn, and preferably between exceed about 5% and exceed in the scope between about 100% than filament diameter.
Thereby in advantageously being attached to, connection element 16 is attached on the inking device (not shown) by removable on the near-end of element 11 with taking off.Rounded obturator tip 17 can be attached on the far-end of interior element 11.
In above-mentioned most preferred embodiment, the hydrogel of intermediary element 12 produces when being exposed to aqueous environment (for example blood) and expands or swelling.Gel preferably is expanded to the volume between about 2 times and about 20 times of its initial volume.Like Fig. 3 and shown in Figure 4; Thereby produce spiral shaped openings that swelling or expansible intermediary element 12 limit between the turn of portion's section through the pine at external component 13 or gap stretch out form wavy in convex curved surface; Said surface limits the chain of arc or circular segments, and the diameter that each section is had is much larger than the diameter of external component 13.
Above-mentioned helical outer element 13 can be considered to limit single spiral shaped openings or gap, or it can be regarded as and limit a plurality of continuous openings or gap, and each said opening or gap are limited between the adjacent paired winding of turn of external component 13.Another kind of optional mode is; If external component 13 for example is shaped as the pipeline of band slit; Then external component 13 will be considered in its axial intermediate section, limit a plurality of discrete openings or gap, and said opening or gap are equivalent to the one or more spiral shaped openings that limit in the illustrated embodiment on function.
Thereby device 10 can be configured so that to make each coaxial element to have different radial thickness different manipulation characteristics is provided.Interior element 11 preferably has the diameter between about 0.075mm and 0.75mm; Intermediary element 12 has the thickness between about 0.025mm and 1.00mm; And external component 13 has the thickness between about 0.025mm and 0.25mm.For the embodiment that utilizes expandable intermediary element 12, these thickness record under unswollen state.The external diameter of external component 13 preferably in fact will be more or less less than the diameter under swelling state or the solvent swelling state that is in of intermediary element 12, thereby make that intermediary element will be easy to expand through opening in the external component 13 or gap.
Fig. 5 and Fig. 6 show the modification of the preferred embodiments of the present invention, and wherein interior element has multiple structure.Especially, Fig. 5 shows first modification with the interior element that comprises the first coaxial turn 110a and the second coaxial turn 110b respectively.Fig. 6 shows second modification with the interior element that comprises the first coaxial turn 210a, the second coaxial turn 210b and the 3rd coaxial turn 210c respectively.In the publication number of total and common pending trial is 2004/0006363 U.S. Patent application, suitable coaxial coil structures and manufacturing approach thereof are disclosed, the disclosure content of said patent application is cited at this as a reference.Interior element can in fact comprise four or more a plurality of coaxial layers.Similarly, external component 13 can comprise a plurality of coaxial helical coil layers, and the surf zone that accounts for suitable percentage ratio in the surf zone of imagination external component keeps open state so that expose intermediary element, as mentioned above.
Fig. 7 shows the 3rd modification of the present invention, and wherein interior element comprises the helical coil 310 that limits axial lumen, is filled with solid core member 320 at least quite long part of said axial lumen length.Solid core member 320 can be impregnated with the treatment preparation, and said treatment preparation can be inhaled in the blood flow.
Fig. 8 shows the 4th modification of the present invention, and wherein interior element comprises the helical coil 410 that limits axial lumen, and at least quite long part of said axial lumen comprises the tubular core member 420 of hollow.This tubular core member 340 provides added strength, and wherein inflatable has the liquid therapeutic agent (not shown).
Fig. 9 show vascular occluding device 10 according to another optional embodiment of the present invention '.This embodiment comprise have distal end sections 15 ' external component 13 ', said distal end sections do not carry out close around, account for about 5% to 100% the little gap of making the external component 13 ' used tinsel or the diameter of filament but be manufactured with.These gaps make device 10 ' distal end sections 15 ' external component 13 ' with the zone of interior element 11 ' overlapping in have bigger flexibility.
In the embodiment shown in fig. 9, interior element 11 ' with external component 13 ' near-end all advantageously through soldering or welding be attached to connection element 16 ' on.Interior element 11 ' with external component 13 ' with connection element 16 ' attached make device 10 ' near-end stronger to the toleration that is out of shape in configuration and implantation process.
Among any embodiment in the above-described embodiments, the part of external component and/or the part of intermediary element can be modified (for example through applying) thereby are comprised the agglutinating structure that has promoted useful cell or somatomedin.In publication number is 2002/0049495 U.S. Patent application, disclosed the typical coating of using for this purpose, the disclosure content of said patent application is cited at this as a reference.
As stated, the present invention provides good trackability in microtubular.In other words, make and to be easy to advance through conduit not and can be leaned against on the conduit or conduit is moved by bundle.This advantage realizes by means of alleviating friction and the flexing located in the end of device.Device is advanced through the required power of typical microcatheter usually less than about 0.7 pound (lbs).
This device preferably can be torn open from quilt on flexible, elongate transmission equipment (not shown) such as tinsel, pusher pipeline or the similar devices and taken off.Typical case known in the art tears the system of taking off open and comprises electrolysis, machinery, electromechanical, heat, ultrasound wave and hydraulic detachment off line structure.This device can be shaped as secondary configuration, like helical coil, hemisphere, ovoid or field of microcoil vaso-occlusive known any other suitable two dimension or 3D shape.Another kind of optional mode is that this device can keep more straight configuration relatively, and has or do not have curvature (for example " J " configuration) at the place, end.
Among any embodiment in the above-described embodiments; Arbitrary element in interior element or the intermediary element or two kinds of elements can be formed so that have stronger stretch-proof property, thereby if make device need by partially retracted in case reorientate or other operation time limit system the stretching of whole device (comprising external component).Be to be appreciated that the multiple material in the above-mentioned material has stretch-proof property in various degree.
This device can be used for other tubulose in blood vessel, other tremulous pulse space such as aneurysm and the whole human body or cryptomere organ or space are carried out obturation and/or thromboembolism.Can utilize the application-specific of this device to comprise aptly cerebral aneurysm, aortic aneurysm, fistula, fallopian tube, heart septal defect, patent foramen ovale and left auricle are carried out obturation.For some application during these are used, possibly preferably utilize the device that has greater than the size of above-mentioned those sizes.
Although in this description and accompanying drawing, the preferred embodiments of the present invention are described, are to be appreciated that those skilled in the relevant art can be easy to make multiple change and modification.Therefore, scope of the present invention is not limited to said specific embodiment and instance, but should be regarded as other optional embodiment and the equivalent way that comprises that the claims below reading are aptly determined.
Claims (25)
1. vascular occlusion implant, said vascular occlusion implant comprises:
Element in the elongated flexible, filamentous;
The nonmetal intermediary element that coaxially centers on said interior element and closely contact with said interior element; With
Coaxially around the external component of said intermediary element, said external component limits the open area, and said intermediary element comes out through said open area;
Wherein said open area comprises two end sections that separated by more most implant length; The open area of said end sections account for implant surface zone in the predetermined portions of said implant length less than about 20%, and said more most open area account for implant surface zone in the predetermined portions of said implant length at least about 20%.
2. vascular occlusion implant according to claim 1, wherein said intermediary element comprises the expandable polymer material.
3. vascular occlusion implant according to claim 1, wherein said external component comprises helical coil, and said helical coil has the pitch that limits said open area, and said intermediary element comes out through said open area.
4. vascular occlusion implant according to claim 3, wherein said turn is formed by the filament of spiral wound, and the said pitch of wherein said turn is greater than the diameter of said filament.
5. vascular occlusion implant according to claim 4, the said pitch of wherein said turn exceeds about 5% and exceed in the scope between about 100% between the diameter than said filament.
6. vascular occlusion implant according to claim 2, wherein said expandable polymer material comprises hydrogel.
7. vascular occlusion implant according to claim 6, wherein said expandable polymer material mainly is made up of hydrogel.
8. vascular occlusion implant according to claim 7, wherein said hydrogel is in response to the variation of ambient parameter and carries out expansible type.
9. vascular occlusion implant according to claim 8, wherein said ambient parameter is selected from the cohort that comprises temperature and pH.
10. vascular occlusion implant according to claim 1, wherein said interior element limits the lumen that comprises the hollow tubular core element.
11. vascular occlusion implant according to claim 1, wherein said interior element limits the lumen that comprises solid substantially core element.
12. vascular occlusion implant according to claim 1, wherein said at least one element in element and the said intermediary element comprise being selected from and comprise medicine, biologically active agents, treatment material with at least a cohort in chemical compound, cell material, gene, collagen and the protein.
13. vascular occlusion implant according to claim 1, wherein said bigger part has covered at least 75% of said implant total length.
14. a vascular occlusion implant, said vascular occlusion implant comprises:
Element in thread;
The nonmetal intermediary element that coaxially centers on said interior element and closely contact with said interior element; With
Coaxially around said intermediary element and have the external component of open area; Said intermediary element comes out through said open area; Said external component comprises the filament of the spiral wound that limits helical coil, and said turn has the pitch greater than the diameter of said filament;
Wherein said open area comprises two end sections that separated by more most implant length; The open area of said end sections account for implant surface zone in the predetermined portions of said implant length less than about 20%, and said more most open area account for implant surface zone in the predetermined portions of said implant length at least about 20%.
15. vascular occlusion implant according to claim 14, at least one element in wherein said interior element and the said intermediary element is processed by nonmetallic material with biocompatibility at least in part.
16. vascular occlusion implant according to claim 15, the said pitch of wherein said turn exceeds about 5% and exceed in the scope between about 100% between the diameter than said filament.
17. vascular occlusion implant according to claim 14; Element comprises the microcoils of being processed by the material with biocompatibility that is selected from the cohort that has comprised tinsel and polymer filament in wherein said, and wherein said intermediary element is formed by the polymeric material with biocompatibility.
18. vascular occlusion implant according to claim 14, wherein said intermediary element comprises the expandable polymer material.
19. vascular occlusion implant according to claim 14, wherein said bigger part has covered at least 75% of said implant total length.
20. vascular occlusion implant according to claim 18, wherein said expandable polymer material comprises hydrogel.
21. vascular occlusion implant according to claim 20, wherein said expandable polymer material mainly is made up of hydrogel.
22. vascular occlusion implant according to claim 21, wherein said hydrogel is in response to the variation of ambient parameter and carries out expansible type.
23. vascular occlusion implant according to claim 22, wherein said ambient parameter is selected from the cohort that comprises temperature and pH.
24. vascular occlusion implant according to claim 14; Element has near-end and far-end in wherein said; And wherein said external component is included in the pine of extending between proximal segment and the distal end sections around the helical coil part; Said proximal segment and distal end sections respectively contiguous said in the position of said near-end and said far-end of element be attached to said on the element, wherein said pine is around partly limiting said open area.
25. vascular occlusion implant according to claim 14, wherein said at least one element in element and the said intermediary element comprise being selected from and comprised medicine, biologically active agents, treatment material with at least a cohort in chemical compound, cell material, gene, collagen and the protein.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US10/631,981 US8273100B2 (en) | 2002-07-31 | 2003-07-31 | Three element coaxial vaso-occlusive device |
| US11/089,207 US20050171572A1 (en) | 2002-07-31 | 2005-03-24 | Multi-layer coaxial vaso-occlusive device |
| US11/089207 | 2005-03-24 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2006800182802A Division CN101198280B (en) | 2005-03-24 | 2006-03-17 | Multi-layer coaxial vaso-occlusive device |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN101978934A CN101978934A (en) | 2011-02-23 |
| CN101978934B true CN101978934B (en) | 2012-10-03 |
Family
ID=43123522
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2010102779962A Expired - Fee Related CN101978934B (en) | 2003-07-31 | 2006-03-17 | Multi-layer coaxial vaso-occlusive device |
Country Status (2)
| Country | Link |
|---|---|
| CN (1) | CN101978934B (en) |
| CA (1) | CA2717255C (en) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9878132B2 (en) | 2012-06-15 | 2018-01-30 | W. L. Gore & Associates, Inc. | Vascular occlusion and drug delivery devices, systems, and methods |
| BR112015022327A2 (en) * | 2013-03-12 | 2017-07-18 | Pfm Medical Inc | vascular occlusion device configured for children |
| WO2018181179A1 (en) | 2017-03-30 | 2018-10-04 | テルモ株式会社 | Medical instrument with hydrophilic member and hydrophobic member laminated |
| CN109350168A (en) * | 2018-12-13 | 2019-02-19 | 威海维心医疗设备有限公司 | Embolization device |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5415634A (en) * | 1990-08-23 | 1995-05-16 | Devices For Vascular Intervention, Inc. | Catheter having helical inflation lumen |
| US5766192A (en) * | 1995-10-20 | 1998-06-16 | Zacca; Nadim M. | Atherectomy, angioplasty and stent method and apparatus |
| US5976162A (en) * | 1996-04-10 | 1999-11-02 | Target Therapeutics, Inc. | Soft-ended fibered micro vaso-occlusive devices |
| WO2002005731A1 (en) * | 2000-07-18 | 2002-01-24 | Teitelbaum George P | Biocompatible, expansile material and stent |
| CN1376041A (en) * | 1999-10-04 | 2002-10-23 | 微温森公司 | Filamentous embolic device with expansible elements |
-
2003
- 2003-07-31 CA CA2717255A patent/CA2717255C/en not_active Expired - Fee Related
-
2006
- 2006-03-17 CN CN2010102779962A patent/CN101978934B/en not_active Expired - Fee Related
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5415634A (en) * | 1990-08-23 | 1995-05-16 | Devices For Vascular Intervention, Inc. | Catheter having helical inflation lumen |
| US5766192A (en) * | 1995-10-20 | 1998-06-16 | Zacca; Nadim M. | Atherectomy, angioplasty and stent method and apparatus |
| US5976162A (en) * | 1996-04-10 | 1999-11-02 | Target Therapeutics, Inc. | Soft-ended fibered micro vaso-occlusive devices |
| CN1376041A (en) * | 1999-10-04 | 2002-10-23 | 微温森公司 | Filamentous embolic device with expansible elements |
| WO2002005731A1 (en) * | 2000-07-18 | 2002-01-24 | Teitelbaum George P | Biocompatible, expansile material and stent |
Also Published As
| Publication number | Publication date |
|---|---|
| CA2717255C (en) | 2015-09-29 |
| CN101978934A (en) | 2011-02-23 |
| CA2717255A1 (en) | 2004-02-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101198280B (en) | Multi-layer coaxial vaso-occlusive device | |
| JP4425789B2 (en) | Three-element coaxial vessel occlusion device | |
| AU2008207620B2 (en) | Filamentous embolic device with expansible elements | |
| US20190046210A1 (en) | Embolic Device With Shaped Wire | |
| JP4383746B2 (en) | Method for producing inflatable thread-like embolic device | |
| US6602261B2 (en) | Filamentous embolic device with expansile elements | |
| CA2385615C (en) | Filamentous embolic device with expansible elements | |
| CN101978934B (en) | Multi-layer coaxial vaso-occlusive device | |
| CN1671330B (en) | Three-part coaxial vaso-occlusive device |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C17 | Cessation of patent right | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20121003 Termination date: 20130317 |